In the both CT26 (hot) and B16F10 (cold) tumor model mice, this nanovaccine could target primary tumors, enhance immune responses to anti-PD-1 treatments by converting cold tumors into hot ones, and modulate systemic immunity to inhibit metastasis [[95], [96], [97]]. The gene discussed is PDCD1; the disease is neoplasm.